Can we Boost Emicizumab Without Increasing Thrombosis Risk? – RPTH Journal
RPTH Journal shared a post on LinkedIn:
”Can we boost emicizumab without increasing thrombosis risk?
Emicizumab transformed hemophilia A care.
But breakthrough bleeding still happens, and treatment options remain imperfect.
A new RPTH study explores a provocative idea:
What if adding low-dose FIX plus FX together could safely enhance emicizumab-driven coagulation?
Here’s the key signal:
Combined FIX/FX supplementation restored coagulation potential to near-normal levels in vitro, in patient samples, and in hemophilia A mice.
Why this is biologically plausible:
- Emicizumab works by bridging FIXa and FX
- More FIX + FX to more ternary complex formation
- ~2× increase in FIX–emicizumab–FX complexes predicted
- Faster clot formation and reduced bleeding in vivo
- Thrombotic markers did not increase in animal models
Translation:
Rather than pushing bypassing agents harder, we may be able to optimize the emicizumab pathway itself.
Big questions for clinicians and researchers:
- Could FIX+FX become an alternative to rFVIIa for breakthrough bleeds?
- Could this strategy reduce treatment burden and dosing frequency?
- How do we balance enhanced hemostasis with real-world thrombosis risk?”
Title: Augmented emicizumab-driven coagulation potential in hemophilia A state by in vitro and in vivo supplementation of combined factors IX and X
Authors: Mitsumasa Osuna, Yuto Nakajima, Eisuke Takami, Hirotoshi Nakano, Keiji Nogami
Find the Full Article on RPTH.”
Stay updated with Hemostasis Today.
-
May 22, 2026, 13:31Mariam Swidan: Why Hemolysis Severity Matters in G6PD Deficiency
-
May 22, 2026, 13:25Augustina Isioma Ikusemoro: Why Plasma and RBC Transfusions Follow Different Compatibility Rules
-
May 22, 2026, 13:08Anas Hamad: Thrombosis as Overlooked Clinical Challenge in APL
-
May 22, 2026, 12:29Neema Ngugi: Highlighting 6 Major Types of Anemia
-
May 22, 2026, 12:27Jacinto López Sagaseta: Solving the Structural Puzzle of FVIIa–EPCR Interaction
-
May 22, 2026, 12:25Shehab Mohamed: Exploring the Emerging Link Between JAK2 Mutations and Thoracic Aortic Aneurysms
-
May 22, 2026, 11:52Prakash W. Kamat: Highlighting the Role of Physical Activity in Hemophilia Management
-
May 22, 2026, 11:43Mohamed Hanafy Morsy: Understanding Hemochromatosis – Genetics Made Simple
-
May 22, 2026, 10:23Rucha Patil: Insights from The National Haemophilia Conclave 2026